As per the prescribing information , brigatinib should be given at a daily dose of 90 mg for the first week, after which the dose should be increased to 180 mg/day.

Brigatinib has also recently been approved for use in this population by the US FDA. --- Paclitaxel has also been granted a positive opinion for marketing authorisation.

Treatment with brigatinib is associated with better outcomes than crizotinib in patients with anaplastic lymphoma kinase translocation-positive advanced non-small-cell lung cancer who have not received prior ALK-targeted therapy, indicate phase III trial results.

Patients with anaplastic lymphoma kinase translocation-positive non-small-cell lung cancer that has metastasized to the central nervous system derive benefit from treatment with brigatinib, suggests an analysis of two trials.

medwireNews : Brigatinib has received accelerated approval from the FDA for the treatment of metastatic non-small-cell lung cancer that has tested positive for the anaplastic lymphoma kinase ( ALK ) rearrangement.

We can also use other drugs like brigatinib, for instance, or alectinib, and the effect of those drugs can lead to other mutations.

Results Among 584 reported psychiatric AEs, 95 cases were selected as potentially treatment related, with higher reporting frequency for lorlatinib (26, 2.8%), followed by brigatinib (10, 1.2%), alectinib (18, 0.7%), ceritinib (12, 0.6%), and crizotinib (29, 0.3%).

Ross Camidge comments on the advanced non-small-cell lung cancer research that caught his attention at the ESMO Congress 2019, including the FLAURA and CheckMate 227 overall survival data, and updates on brigatinib and lorlatinib (3:01).

Tejas Patil rounds up findings from the ALEX, ALTA-1L, ARROW, LIBRETTO-001, GEOMETEY mono-1 and VISION studies of non-small-cell lung cancer patients with ALK, RET, or MET alterations (9:56).

Median progression-free survival in the total study population was 9.6 months, which compares favorably with other second- and third-generation ALK inhibitors, namely ceritinib (5.7 months) alectinib (8.3 months), and brigatinib (12.9 months).

. © 2019 Springer Healthcare part of the Springer Nature group See also: Brigatinib, paclitaxel, biosimilar pegfilgrastims receive EMA approvals Copanlisib, low-dose cabazitaxel receive FDA go ahead

. © 2018 Springer Healthcare part of the Springer Nature group See also: Avelumab-lorlatinib shows efficacy for heavily pretreated ALK-positive NSCLC Lorlatinib active against ALK, ROS1-rearranged NSCLC Brigatinib has intracranial activity in patients with ALK-rearranged NSCLC

Pacheco added that “the next generation ALK inhibitors we used more commonly immediately post-crizotinib were the highly CNS penetrant next-generation ALK inhibitors alectinib and brigatinib,” and many of the patients were enrolled in clinical trials.